ATE469144T1 - Substituierte pyridonverbindungen und anwendungsverfahren - Google Patents

Substituierte pyridonverbindungen und anwendungsverfahren

Info

Publication number
ATE469144T1
ATE469144T1 AT07810612T AT07810612T ATE469144T1 AT E469144 T1 ATE469144 T1 AT E469144T1 AT 07810612 T AT07810612 T AT 07810612T AT 07810612 T AT07810612 T AT 07810612T AT E469144 T1 ATE469144 T1 AT E469144T1
Authority
AT
Austria
Prior art keywords
methods
compounds
mediated diseases
kit
pyridone compounds
Prior art date
Application number
AT07810612T
Other languages
English (en)
Inventor
Essa Hu
Jason Human
Roxanne Kunz
Andrew Tasker
Ryan White
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Application granted granted Critical
Publication of ATE469144T1 publication Critical patent/ATE469144T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
AT07810612T 2006-07-20 2007-07-17 Substituierte pyridonverbindungen und anwendungsverfahren ATE469144T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US83236806P 2006-07-20 2006-07-20
PCT/US2007/016382 WO2008011109A2 (en) 2006-07-20 2007-07-17 Substituted pyridone compounds and methods of use

Publications (1)

Publication Number Publication Date
ATE469144T1 true ATE469144T1 (de) 2010-06-15

Family

ID=38812055

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07810612T ATE469144T1 (de) 2006-07-20 2007-07-17 Substituierte pyridonverbindungen und anwendungsverfahren

Country Status (8)

Country Link
US (2) US7700607B2 (de)
EP (1) EP2079724B1 (de)
AT (1) ATE469144T1 (de)
AU (1) AU2007275682B2 (de)
CA (1) CA2658462C (de)
DE (1) DE602007006835D1 (de)
ES (1) ES2344760T3 (de)
WO (1) WO2008011109A2 (de)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1831225A2 (de) 2004-11-19 2007-09-12 The Regents of the University of California Entzündungshemmende pyrazolopyrimidine
WO2007114926A2 (en) 2006-04-04 2007-10-11 The Regents Of The University Of California Kinase antagonists
DE602007006835D1 (de) * 2006-07-20 2010-07-08 Amgen Inc Substituierte pyridonverbindungen und anwendungsverfahren
GB2467670B (en) * 2007-10-04 2012-08-01 Intellikine Inc Chemical entities and therapeutic uses thereof
MX2010007419A (es) 2008-01-04 2010-11-12 Intellikine Inc Ciertas entidades quimicas, composiciones y metodos.
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
EP2252293B1 (de) 2008-03-14 2018-06-27 Intellikine, LLC Kinasehemmer und verwendungsverfahren
US8993580B2 (en) 2008-03-14 2015-03-31 Intellikine Llc Benzothiazole kinase inhibitors and methods of use
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
BRPI0915231A2 (pt) 2008-07-08 2018-06-12 Intellikine Inc compostos inibidores de quinase e métodos de uso
US20110224223A1 (en) * 2008-07-08 2011-09-15 The Regents Of The University Of California, A California Corporation MTOR Modulators and Uses Thereof
CA2738429C (en) 2008-09-26 2016-10-25 Intellikine, Inc. Heterocyclic kinase inhibitors
EP2358720B1 (de) 2008-10-16 2016-03-02 The Regents of The University of California Heteroarylkinasehemmer mit kondensierten ringen
US8476431B2 (en) 2008-11-03 2013-07-02 Itellikine LLC Benzoxazole kinase inhibitors and methods of use
JP5789252B2 (ja) 2009-05-07 2015-10-07 インテリカイン， エルエルシー 複素環式化合物およびその使用
WO2010135470A1 (en) * 2009-05-19 2010-11-25 Intermune, Inc. Pifenidone derivatives for treating bronchial asthma
WO2011047384A2 (en) 2009-10-16 2011-04-21 The Regents Of The University Of California Methods of inhibiting ire1
CA2799579A1 (en) 2010-05-21 2011-11-24 Intellikine, Inc. Chemical compounds, compositions and methods for kinase modulation
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
ES2637113T3 (es) 2011-01-10 2017-10-10 Infinity Pharmaceuticals, Inc. Procedimientos para preparar isoquinolinonas y formas sólidas de isoquinolinonas
US9295673B2 (en) 2011-02-23 2016-03-29 Intellikine Llc Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof
AR088218A1 (es) 2011-07-19 2014-05-21 Infinity Pharmaceuticals Inc Compuestos heterociclicos utiles como inhibidores de pi3k
HK1198443A1 (en) 2011-07-19 2015-04-24 无限药品股份有限公司 Heterocyclic compounds and uses thereof
MX2014002542A (es) 2011-08-29 2014-07-09 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos.
CA2846496C (en) 2011-09-02 2020-07-14 The Regents Of The University Of California Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US8828998B2 (en) 2012-06-25 2014-09-09 Infinity Pharmaceuticals, Inc. Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
BR112014030284B1 (pt) * 2012-07-18 2021-11-30 Sunshine Lake Pharma Co., Ltd Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
JP2015532287A (ja) 2012-09-26 2015-11-09 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア Ｉｒｅ１の調節
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
AU2013337717B2 (en) 2012-11-01 2018-10-25 Infinity Pharmaceuticals, Inc. Treatment of cancers using PI3 kinase isoform modulators
US9481667B2 (en) 2013-03-15 2016-11-01 Infinity Pharmaceuticals, Inc. Salts and solid forms of isoquinolinones and composition comprising and methods of using the same
US9751888B2 (en) 2013-10-04 2017-09-05 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PT3052485T (pt) 2013-10-04 2021-10-22 Infinity Pharmaceuticals Inc Compostos heterocíclicos e suas utilizações
MX382033B (es) 2014-03-19 2025-03-13 Infinity Pharmaceuticals Inc Compuestos heterocíclicos para utilizarlos en el tratamiento de trastornos mediados por pi3k-gamma.
MX382781B (es) * 2014-04-02 2025-03-13 Intermune Inc Piridinonas anti-fibroticas.
WO2015160975A2 (en) 2014-04-16 2015-10-22 Infinity Pharmaceuticals, Inc. Combination therapies
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9321766B1 (en) 2014-10-06 2016-04-26 Allergan, Inc. Kinase inhibitors
AU2015369712B2 (en) * 2014-12-22 2020-05-07 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Mutant IDH1 inhibitors useful for treating cancer
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
BR112017013440A2 (pt) 2014-12-24 2018-01-09 Gilead Sciences, Inc. compostos de isoquinolina para o tratamento de hiv
WO2017048702A1 (en) 2015-09-14 2017-03-23 Infinity Pharmaceuticals, Inc. Solid forms of isoquinolinone derivatives, process of making, compositions comprising, and methods of using the same
IL294124B2 (en) 2015-12-10 2024-02-01 Ptc Therapeutics Inc Methods for treating huntington's disease
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
WO2017214269A1 (en) 2016-06-08 2017-12-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
SG11201811237WA (en) 2016-06-24 2019-01-30 Infinity Pharmaceuticals Inc Combination therapies
US11407753B2 (en) * 2017-06-05 2022-08-09 Ptc Therapeutics, Inc. Compounds for treating Huntington's disease
US11382918B2 (en) 2017-06-28 2022-07-12 Ptc Therapeutics, Inc. Methods for treating Huntington's Disease
WO2019005993A1 (en) 2017-06-28 2019-01-03 Ptc Therapeutics, Inc. METHODS OF TREATING HUNTINGTON'S DISEASE
MX2020009957A (es) 2018-03-27 2021-01-15 Ptc Therapeutics Inc Compuestos para el tratamiento de enfermedad de hungtinton.
EP3814345B8 (de) 2018-06-27 2024-10-30 PTC Therapeutics, Inc. Heteroaryl verbindungen zur behandlung von morbus huntington
EP3814360B8 (de) 2018-06-27 2024-11-06 PTC Therapeutics, Inc. Heteroaryl verbindungen zur behandlung von morbus huntington
PL3814357T3 (pl) 2018-06-27 2024-09-16 Ptc Therapeutics, Inc. Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
WO2020231977A1 (en) 2019-05-13 2020-11-19 Ptc Therapeutics, Inc. Compounds for treating huntington's disease
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
US11691971B2 (en) 2020-06-19 2023-07-04 Incyte Corporation Naphthyridinone compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
CR20230057A (es) 2020-07-02 2023-08-15 Incyte Corp Compuestos tríciclicos de urea como inhibidores de jak2 v617f
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
AR125273A1 (es) 2021-02-25 2023-07-05 Incyte Corp Lactamas espirocíclicas como inhibidores de jak2 v617f
PT4426434T (pt) 2021-11-02 2025-11-24 Flare Therapeutics Inc Agonistas inversos de pparg e suas utilizações
AU2023235313A1 (en) 2022-03-17 2024-10-03 Incyte Corporation Tricyclic urea compounds as jak2 v617f inhibitors
CN119101030A (zh) * 2023-09-08 2024-12-10 北京华益健康药物研究中心 用于治疗或预防冠状病毒感染的3cl蛋白酶抑制剂及其用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
ATE331514T1 (de) 1999-12-22 2006-07-15 Sugen Inc Indolinonderivate zur abänderung der c-kit tyrosinproteinkinase
WO2003002109A2 (en) 2001-06-29 2003-01-09 Ab Science Use of tyrosine kinase inhibitors for treating autoimmune diseases
US7691866B2 (en) * 2003-10-16 2010-04-06 Novartis Vaccines And Diagnostics, Inc. 2,6-disubstituted quinazolines, quinoxalines, quinolines and isoquinolines and methods of their use as inhibitors of Raf kinase
US20070054916A1 (en) * 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
DE602007006835D1 (de) 2006-07-20 2010-07-08 Amgen Inc Substituierte pyridonverbindungen und anwendungsverfahren

Also Published As

Publication number Publication date
US20080249090A1 (en) 2008-10-09
ES2344760T3 (es) 2010-09-06
DE602007006835D1 (de) 2010-07-08
EP2079724A2 (de) 2009-07-22
AU2007275682B2 (en) 2012-05-17
CA2658462C (en) 2011-09-27
EP2079724B1 (de) 2010-05-26
WO2008011109A2 (en) 2008-01-24
WO2008011109A3 (en) 2008-05-08
US20100160312A1 (en) 2010-06-24
CA2658462A1 (en) 2008-01-24
US7700607B2 (en) 2010-04-20
US8063055B2 (en) 2011-11-22
AU2007275682A1 (en) 2008-01-24

Similar Documents

Publication Publication Date Title
ATE469144T1 (de) Substituierte pyridonverbindungen und anwendungsverfahren
WO2008011110A3 (en) Di-amino-substituted heterocyclic compounds and methods of use
EA201290255A1 (ru) Способы и композиции для лечения рака
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
UA107188C2 (uk) Карбоксамідні похідні хіназолінів або хінолінів та фармацевтична композиція на їх основі
MA32811B1 (fr) Nouveaux composés
EA201000100A1 (ru) Гетероциклические соединения, полезные в качестве ингибиторов mk2
ATE517882T1 (de) Chinolinderivate
EA201100311A1 (ru) Амидные производные гетероарилов и их применение в качестве активаторов глюкокиназы
SMT201200017B (it) Nuovi antagonisti P2X7R e il loro uso.
EA201100524A1 (ru) Азаиндазолы в качестве антагонистов рецептора ccr1
MA33937B1 (fr) Composes pyrazole comme antagonistes du recepteur crth2
EA201390969A1 (ru) Модуляторы глюкагонового рецептора
EA201390908A1 (ru) Производные бицикло[3.2.1]октиламида и их применение
DK2105164T3 (da) Nye P2X7R-antagonister og deres anvendelse
EA201500298A1 (ru) Алкоксипиразолы в качестве активаторов растворимой гуанилатциклазы
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
EP2155203A4 (de) Azaindazol-verbindungen und anwendungsverfahren
ATE456392T1 (de) Benzoädüisoxazol-derivate als c-kit-tyrosinkinase-hemmer zur behandlung von erkrankungen im zusammenhang mit der überproduktion von histamin
MX390264B (es) Antagonistas d2, metodos de sintesis y metodos de uso.
EA201200471A1 (ru) Простые эфирные производные бициклических гетероарилов
EA200970065A1 (ru) Производные пиперазинила, предназначенные для лечения заболеваний, опосредованных рецептором gpr38
EA201270359A1 (ru) Терапевтическое средство от расстройств настроения
MA34094B1 (fr) Dérivés de 3-(hétéroarylamino)-1,2,3,4-tétrahydro-9h-carbazole et leur utilisation comme modulateurs du récepteur de la prostaglandine d2
CR20130041A (es) ISOXAZOLO[5,4-b]PIRIDINAS HERBICIDAS

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties